RecruitingOsteoarthritis · Overweight and Obesity
Study for People With Excess Body Weight and Knee Osteoarthritis
Montreal, Quebec
Psoriasis is a long-term condition in which the immune system drives skin cells to build up faster than usual, forming raised patches called plaques. The patches can itch, burn or crack, and they tend to come and go in flares. It is now understood as an inflammatory condition that can affect the joints and other parts of the body as well as the skin.
It is not contagious. You cannot catch psoriasis from someone else or pass it on by touch, and it is not caused by poor hygiene. It is also not only a skin problem: the same inflammation is linked to joint disease, and clinicians in Canada now ask about the joints as a standard part of the assessment.
Psoriasis also does not look the same on every skin tone. On lighter skin, plaques often appear red or pink with silvery scale. On darker skin they can look purple, brown or grey, which can make them harder to recognise. A Canadian consensus paper has identified gaps in psoriasis care for people with skin of colour, and that is one of the things current research is trying to close.
How much skin is involved, and where, differs greatly from person to person, and the same person can have quiet months followed by a flare.

Some things cannot be changed:
Others can often be worked on, usually with support from a health care team:
Psoriasis is usually diagnosed by a family doctor, nurse practitioner or dermatologist based on how the skin, scalp and nails look and where the patches are. A skin biopsy is sometimes taken when the appearance is unclear, or to tell psoriasis apart from other skin conditions. Because psoriatic arthritis is common, clinicians also ask about joint pain, morning stiffness and swelling, and may refer you to a rheumatologist.
Clinical research for Psoriasis is enrolling. See the current studies
Care in Canada is chosen according to how much skin is involved, which areas are affected, whether the joints are involved, and what else is going on with your health. Depending on your situation and what matters to you, a health care team may discuss:
Access is not the same everywhere. Canadian reports document that biologic use varies with income, from 4% among people in the lowest income bracket to 14% in the highest, and coverage differs by province and territory. What suits one person will not suit another, and which of these applies to you is a decision for you and your own clinician. This page is not a recommendation about any of them.
It is still not established why psoriasis develops in some people, why response to the same treatment varies so widely between individuals, or how to predict who will go on to develop psoriatic arthritis. Canada has no national prevalence figure either: the strongest Canadian measurement comes from Ontario health administrative records and reflects 2015, and it does not match the national organisational estimate when scaled up. Canadian reports also document unequal access by income, and gaps in care for people with skin of colour. Research now under way includes new and comparative biologic targets, targeted oral small molecules, treat-to-target strategies aimed at limiting long-term cumulative impact, biomarkers to predict psoriatic arthritis, and work on diagnosis and severity assessment across the full range of skin tones.
Clinical studies are how those questions get answered. Taking part is voluntary, you give informed consent before anything begins, and you can stop at any time without affecting the care you get from your own doctor. Joining a study does not mean giving up your current treatment, and no one can tell in advance whether a study will help you personally.
This page is written in plain language for people considering clinical research. It is general health information, not medical advice, and it does not replace a conversation with your own doctor or nurse practitioner.
An ICES population-based study found a prevalence of 2.54% among Ontario adults in 2015, equal to 273,238 people in that province. The Canadian Dermatology Association states that psoriasis affects 1 million Canadians nationally. The two figures come from different methods, one from health administrative records in a single province and one from a national organisation.
Yes. The Canadian Dermatology Association reports that up to 30% of people with psoriasis have or will develop arthritis, and the ICES study found psoriatic arthritis in 0.17% of the Ontario adult population. Joint pain, morning stiffness or swelling of fingers or toes is worth raising with a clinician.
No. Canadian care ranges from topical treatments through phototherapy, oral systemic medicines and several classes of biologic medicines, and the choice depends on severity, the areas affected, joint involvement and other health conditions. Canadian reports also document that access to biologics varies by income and by province.
RecruitingOsteoarthritis · Overweight and Obesity
Montreal, Quebec
Recruiting
RecruitingOsteoarthritis · Overweight and Obesity
Toronto & Stouffville, Ontario
RecruitingType 2 Diabetes · Overweight and Obesity
Sarnia & Hamilton, Ontario
Recruiting
Recruiting